

New High Risk HPV Test

Effective January 13, 2011 Pathology Medical Services, PC will perform in house High Risk HPV testing with Cervista™ HPV HR, a FDA approved screening test for 14 high risk HPV (human papillomavirus) types associated with cervical cancer and its precursor conditions.

Indications for Cervista™ HPV HR testing include:

- To screen patients with ASCUS cervical cytology to determine the need for referral to colposcopy
- In women ≥ 30 , use with cervical cytology to screen for the presence or absence of high-risk HPV types

Specimen requirements: Cervical pap specimen collected using Broom-type (Rovers Cervex® Brush, Wallach Papette®) or Endocervical Brush/Spatula collection device/s submitted in **ThinPrep®** or **SurePath™** pap vial.

Cervista™ methodology includes an internal control for the presence of human DNA in each patient sample. Specimens with low cellularity or contaminating substances* may have insufficient human DNA present for valid testing, causing an “Insufficient or Indeterminate” result.

***Note:** contamination of the cervix with lubricant, contraceptive jelly, or anti-fungal creams (clotrimazole or miconazole), may result in an insufficient specimen for HPV testing.

Stability: Thin Prep® and SurePath™ specimens are stable for up to 30 days.

New Test Code: 87623

CPT Code: 86721